Literature DB >> 2492108

Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.

J Sanchez1, J Holmgren.   

Abstract

We have constructed an overexpression system in which the gene encoding the B subunit of cholera toxin (CTB) was placed under the control of the strong tacP promoter in a wide host range plasmid. Recombinant nontoxigenic classical and E1 Tor Vibrio cholerae strains of different serotypes harboring this plasmid excreted 10- to 100-fold higher amounts of CTB than any other wild-type or recombinant strain tested and may therefore be useful killed oral vaccine strains. The manipulations to place the CTB gene under tacP also included, by design, the introduction of single enzyme restriction sites for gene fusions to the CTB amino terminus. Cloning into these sites allows construction of CTB-derived hybrid proteins carrying various putative vaccine peptide antigens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492108      PMCID: PMC286494          DOI: 10.1073/pnas.86.2.481

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Comparative analysis of immune electrophoretic precipitates employing a modified immune electrophoretic technique.

Authors:  C WADSWORTH; L A HANSON
Journal:  Int Arch Allergy Appl Immunol       Date:  1960

2.  Covalent structure of the beta chain of cholera enterotoxin.

Authors:  A Kurosky; D E Markel; J W Peterson
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

3.  Determination of the primary structure of cholera toxin B subunit.

Authors:  C Y Lai
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

Review 4.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

5.  A permeability factor (toxin) found in cholera stools and culture filtrates and its neutralization by convalescent cholera sera.

Authors:  J P Craig
Journal:  Nature       Date:  1965-08-07       Impact factor: 49.962

6.  Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates.

Authors:  J B Kaper; H Lockman; M M Baldini; M M Levine
Journal:  Nature       Date:  1984 Apr 12-18       Impact factor: 49.962

7.  Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lysoGM1 ganglioside.

Authors:  J L Tayot; J Holmgren; L Svennerholm; M Lindblad; M Tardy
Journal:  Eur J Biochem       Date:  1981-01

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin.

Authors:  H Lockman; J B Kaper
Journal:  J Biol Chem       Date:  1983-11-25       Impact factor: 5.157

10.  Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin.

Authors:  J Holmgren; P Fredman; M Lindblad; A M Svennerholm; L Svennerholm
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

View more
  41 in total

1.  Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

Authors:  E L Johansson; L Wassén; J Holmgren; M Jertborn; A Rudin
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

Authors:  A Rudin; G C Riise; J Holmgren
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

3.  Transient transcriptional activation of the Vibrio cholerae El Tor virulence regulator toxT in response to culture conditions.

Authors:  A I Medrano; V J DiRita; G Castillo; J Sanchez
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

5.  Production of double repeated B subunit of Shiga toxin 2e at high levels in transgenic lettuce plants as vaccine material for porcine edema disease.

Authors:  Takeshi Matsui; Eiji Takita; Toshio Sato; Michie Aizawa; Misa Ki; Yumiko Kadoyama; Kenji Hirano; Satoko Kinjo; Hiroshi Asao; Keiko Kawamoto; Haruko Kariya; Sou-Ichi Makino; Takashi Hamabata; Kazutoshi Sawada; Ko Kato
Journal:  Transgenic Res       Date:  2010-10-24       Impact factor: 2.788

6.  Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit.

Authors:  T D Bartley; D W Whiteley; V L Mar; D L Burns; W N Burnette
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Molecular cloning of the 3' half of the Clostridium perfringens enterotoxin gene and demonstration that this region encodes receptor-binding activity.

Authors:  P C Hanna; A P Wnek; B A McClane
Journal:  J Bacteriol       Date:  1989-12       Impact factor: 3.490

8.  A classical strain of Vibrio cholerae with diminished ability to process the proteolytically sensitive site in the A subunit of cholera toxin.

Authors:  Y Ichinose; T Tsuji; M Kato; B C Neves; K Morita; M Ehara; T Hirayama
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

9.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

10.  Analysis of expression of toxin-coregulated pili in classical and El Tor Vibrio cholerae O1 in vitro and in vivo.

Authors:  G Jonson; J Holmgren; A M Svennerholm
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.